FindTrial
Sign In

NETest

DEVICE3 trials

Sponsors

Wren Laboratories LLC, H. Lee Moffitt Cancer Center and Research Institute, Academisch Medisch Centrum

Conditions

CarcinoidGastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine NeoplasmNeuroendocrine CarcinomaNeuroendocrine Tumorpancreatic neuroendocrine tumor pNET

Unknown Phase

RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Enrolling by invitationNCT02270567
Wren Laboratories LLCCarcinoid, Neuroendocrine Carcinoma, Neuroendocrine Tumor
Start: 2015-02-28End: 2030-12-31Target: 400Updated: 2025-11-13
NETest in patients with resected pancreatic neuroendocrine tumor
Active, not recruitingNL-OMON44092
Academisch Medisch Centrumpancreatic neuroendocrine tumor pNET
Start: 2015-04-23Target: 30Updated: 2024-02-28
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
CompletedNCT02948946
H. Lee Moffitt Cancer Center and Research InstituteGastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
Start: 2017-01-09End: 2020-09-15Updated: 2021-08-04

Related Papers

NETest2.0® Demonstrates Superior Monitoring Performance Compared with Chromogranin A in Neuroendocrine Tumor Surveillance
Cancers2026-07-09
Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest
Neuroendocrinology2020-05-1121 citations
Sensitivity and specificity of the NETest: A validation study.
Journal of Clinical Oncology2019-01-2913 citations
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study
The Oncologist2018-08-2972 citations